Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ly, Thu
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab	Active, not recruiting	1/2	323	US, RoW	FLX475, pembrolizumab (KEYTRUDA®)	RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC	Advanced Cancer	09/24	01/25